Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Read here for a detailed financial analysis of Medifast stock post-pandemic, GLP-1 impact, and the company's collaboration ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...

Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Official data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the ...